PETALING JAYA: CIMB Research has initiated coverage on Karex Bhd with a “buy” rating and target price of RM1.60.

It said the condom maker was entering a structural earnings upcycle, driven by the transition of its patented nitrile synthetic condom moving from pilot launch to mass market commercialisation.

“Its exclusive global partner (customer D) has expanded distribution to 18 countries with a full global rollout underway.

“This marks a shift from research and development investment to earnings delivery, as nitrile production capacity is set to grow five times to 900 million pieces per annum by end of financial year ending June 30, 2028 (FY28),” it told clients.
大行全看好的 1.2✓1.4✓1.6✓ 现在呢0.645.....